Safety of onartuzumab in patients with solid tumors: Experience to date from the onartuzumab clinical trial program

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Morley, Roland ^a   Cardenas, Alison ^a   Hawkins, Peter ^a   Suzuki, Yasuyo ^a   Paton, Virginia ^a   Phan, See Chun ^a   Merchant, Mark ^a   Hsu, Jessie ^a   Yu, Wei ^a   Xia, Qi ^a   Koralek, Daniel ^a   Luhn, Patricia ^a   Aldairy, Wassim ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; ONARTUZUMAB; OXALIPLATIN; PACLITAXEL; PLACEBO; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; ARTERIAL THROMBOEMBOLISM; ARTICLE; CANCER PATIENT; DATA ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG SAFETY; EDEMA; EMBOLISM; GLIOBLASTOMA; HUMAN; HYPOALBUMINEMIA; INCIDENCE; METASTATIC COLORECTAL CANCER; NON SMALL CELL LUNG CANCER; SOLID TUMOR; STOMACH CANCER; THROMBOEMBOLISM; THROMBOSIS; TRIPLE NEGATIVE BREAST CANCER; VENOUS THROMBOEMBOLISM; CLINICAL TRIAL (TOPIC); INTESTINAL PERFORATION; NEOPLASMS;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; EDEMA; HUMANS; HYPOALBUMINEMIA; INTESTINAL PERFORATION; NEOPLASMS; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 84948656597     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139679     Document Type: Article

References (56)

1. Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013; 110: E2987-96. doi: 10.1073/pnas.1302725110 PMID: 23882082
2. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12: 89-103. doi: 10.1038/nrc3205 PMID: 22270953
3. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4: 915-25. PMID: 14685170
4. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992; 119: 629-41. PMID: 1383237
5. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest. 2000; 106: 1511-9. PMID: 11120758
6. Chmielowiec J, Borowiak M, Morkel M, Stradal T, Munz B, Werner S, et al. c-Met is essential for wound healing in the skin. J Cell Biol. 2007; 177: 151-62. PMID: 17403932
7. Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P, Desiderio MA. Interaction between humanbreast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer. 2010; 46: 1679-91. doi: 10.1016/j.ejca.2010.02.036 PMID: 20350802
8. Conway K, Price P, Harding KG, Jiang WG. The molecular and clinical impact of hepatocyte growth factor, its receptor, activators, and inhibitors in wound healing. Wound Repair Regen. 2006; 14: 2-10. PMID: 16476066
9. Dignass AU. Mechanisms and modulation of intestinal epithelial repair. Inflamm Bowel Dis. 2001; 7: 68-77. PMID: 11233665
10. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci. 1998; 111: 237-47. PMID: 9405310
11. Bardelli C, Sala M, Cavallazzi U, Prat M. Agonist Met antibodies define the signalling threshold required for a full mitogenic and invasive program of Kaposi's Sarcoma cells. Biochem Biophys Res Commun. 2005; 334: 1172-9. PMID: 16039997
12. Lee JM, Kim B, Lee SB, Jeong Y, Oh YM, Song YJ, et al. Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody. Oncogene. 2014; 33: 34-43. doi: 10.1038/onc.2012. 551 PMID: 23208509
13. Petrelli A, Circosta P, Granziero L, Mazzone M, Pisacane A, Fenoglio S, et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A. 2006; 103: 5090-5. PMID: 16547140
14. Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q, et al. Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET. PLoS One. 2012; 7: e34658. doi: 10.1371/journal.pone.0034658 PMID: 22511956
15. Goetsch L. Novel antibodies inhibiting c-met dimerization, and uses thereof. Publication Number: EP 2188312 A2; Publication Date: 26 May 2010; Application Number: EP 08786050 A; Filing Date: 10 Jul 2008. Available: http://ip.com/pat/EP2188312A2. Accessed: 22 May 2015.
16. Mai E, Zheng Z, Chen Y, Peng J, Severin C, Filvaroff E, et al. Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab. Mol Cancer Ther. 2014; 13: 540-52. doi: 10.1158/1535-7163.MCT-13- 0494 PMID: 24258345
17. Xiang H, Bender BC, Reyes AE II, Merchant M, Jumbe NL, Romero M, et al. Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development. Clin Cancer Res. 2013; 19: 5068-78. doi: 10.1158/1078-0432.CCR-13-0260 PMID: 23894056
18. Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, et al. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. J Clin Pharmacol. 2013; 53: 1103-11. doi: 10.1002/jcph.148 PMID: 23922054
19. Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, et al. Phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma. Neuro Oncol. 2014; 16 (suppl 5): v81 (abstract ET-12).
20. Hirsch FR, Govindan R, Zvirbule Z, Braiteh F, Rittmeyer A, Belda Iniesta C, et al. Efficacy and safety results from a phase 2, placebo-controlled study of onartuzumab plus first-line platinum-doublet chemotherapy in advanced squamous-cell non-small-cell lung cancer (sq NSCLC). Int J Radiat Oncol Biol Phys. 2014; 90 (5 suppl): S37 (abstract 176).
21. Wakelee HA, Zvirbule Z, De Braud F, Kingsley CD, Mekhail T, Schütte W, et al. (2014) Efficacy and safety of onartuzumab in combination with first-line bevacizumab- or pemetrexed-based chemotherapy regimens in advanced nonsquamous non-small cell lung cancer (nsNSCLC): results from a phase 2, placebo-controlled study (GO27821). Int J Radiat Oncol Biol Phys. 2014; 90 (5 suppl): S37-8 (abstract 177).
22. Bendell JC, Hochster HS, Hart LL, Firdaus I, Mace JR, McFarlane JJ, et al. A randomized, doubleblind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2015; 33 (3 suppl) (abstract 663).
23. Diéras V, Yardley DA, Romieu G, Valero V, Isakoff SJ, Koeppen H, et al. A randomized, phase II, multicenter, double-blind, placebo-controlled trial evaluating onartuzumab with or without bevacizumab in combination with weekly paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC). Presented at the 2013 San Antonio Breast Cancer Symposium (abstract P2-16-01).
24. Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Shames DS, Yu W, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol. 2014; 32 (15 suppl) (abstract 8000).
25. Shah MA, Cho JY, Bee Huat IT, Tebbutt NC, Yen C-J, Kang A, et al. Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC). J Clin Oncol. 2015; 33 (suppl 3) (abstract 2).
26. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987; 327: 239-42. PMID: 2952888
27. Miyazawa K, Tsubouchi H, Naka D, Takahashi K, Okigaki M, Arakaki N, et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun. 1989; 163: 967-73. PMID: 2528952
28. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989; 342: 440-3. PMID: 2531289
29. Zarnegar R, Michalopoulos G. Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res. 1989; 49: 3314-20. PMID: 2524251
30. Gherardi E, Stoker M. Hepatocytes and scatter factor. Nature. 1990; 346: 228. PMID: 2142751
31. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991; 251: 802-4. PMID: 1846706
32. Weidner KM, Arakaki N, Hartmann G, Vandekerckhove J, Weingart S, Rieder H, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci U S A. 1991; 88: 7001-5. PMID: 1831266
33. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003; 22: 309-25. PMID: 12884908
34. Ely JW, Osheroff JA, Chambliss ML, Ebell MH. Approach to leg edema of unclear etiology. J Am Board Fam Med. 2006; 19: 148-60. PMID: 16513903
35. Cho S, Atwood JE. Peripheral edema. Am J Med. 2002; 113: 580-6. PMID: 12459405
36. Hou W, Sanyal AJ. Ascites: diagnosis and management. Med Clin North Am. 2009; 93: 801-17. doi: 10.1016/j.mcna.2009.03.007 PMID: 19577115
37. Lawenda BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009; 59: 8-24. doi: 10.3322/caac. 20001 PMID: 19147865
38. Samsky MD, Patel CB, DeWald TA, Smith AD, Felker GM, Rogers JG, et al. Cardiohepatic interactions in heart failure: an overview and clinical implications. J Am Coll Cardiol. 2013; 61:2397-405. doi: 10. 1016/j.jacc.2013.03.042 PMID: 23603231
39. Silverberg DS, Wexler D, Iaina A, Steinbruch S, Wollman Y, Schwartz D. Anemia, chronic renal disease and congestive heart failure-the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol. 2006; 38: 295-310. PMID: 16868702
40. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep. 2002; 4: 479-82. PMID: 12379167
41. Frishman WH. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol. 2002; 89: 18D-25D. PMID: 11909557
42. Birukova AA, Cokic I, Moldobaeva N, Birukov KG. Paxillin is involved in the differential regulation of endothelial barrier by HGF and VEGF. Am J Respir Cell Mol Biol. 2009; 40: 99-107. doi: 10.1165/ rcmb.2008-0099OC PMID: 18664639
43. Saito Y, Nakagami H, Morishita R, Takami Y, Kikuchi Y, Hayashi H, et al. Transfection of human hepatocyte growth factor gene ameliorates secondary lymphedema via promotion of lymphangiogenesis. Circulation. 2006; 114: 1177-84. PMID: 16952986
44. Shin D, Monga SP. Cellular and molecular basis of liver development. Compr Physiol. 2013; 3: 799-815. doi: 10.1002/cphy.c120022 PMID: 23720330
45. Singleton PA, Salgia R, Moreno-Vinasco L, Moitra J, Sammani S, Mirzapoiazova T, et al. CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem. 2007; 282: 30643-57. PMID: 17702746
46. Pietrapiana D, Sala M, Prat M, Sinigaglia F. Met identification on human platelets: role of hepatocyte growth factor in the modulation of platelet activation. FEBS Lett. 2005; 579: 4550-4. PMID: 16083876
47. Shimomura T, Kondo J, Ochiai M, Naka D, Miyazawa K, Morimoto Y, et al. Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem. 1993; 268: 22927-32. PMID: 8226803
48. Miyazawa K. Hepatocyte growth factor activator (HGFA): a serine protease that links tissue injury to activation of hepatocyte growth factor. FEBS J. 2010; 277: 2208-14. doi: 10.1111/j.1742-4658.2010. 07637.x PMID: 20402766
49. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160: 809-15. PMID: 10737280
50. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis. 2006; 21: 23-9. PMID: 16475038
51. Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost. 2006; 32: 651-8. PMID: 17024592
52. Avastin 25 mg/ml concentration for solution for infusion. Summary of product characteristics. Roche Products Ltd. Last updated 27 Oct 2014. Available: http://www.medicines.org.uk/emc/medicine/15748. Accessed: 25 Nov 2014.
53. Kakkar T, Ma M, Zhuang Y, Patton A, Hu Z, Mounho B. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys. Pharm Res. 2007; 24: 1910-8. PMID: 17520181
54. Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, et al. Targeted MET inhibition in castrationresistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013; 19: 215-24. doi: 10.1158/1078-0432.CCR-12- 2605 PMID: 23136195
55. Mok TSK, Park K, Geater SL, Agarwal S, Han M, Credi M, et al. A randomized phase (Ph) 2 study with exploratory biomarker analysis of ficlatuzumab (F), a humanized hepatocyte growth factor (HGF) inhibitory MAb, in combination with gefitinib (G) versus G in Asian patients (pts) with lung adenocarcinoma. Ann Oncol. 2012; 23 (suppl 9): ix389-ix399 (abstract 1198P).
56. Smyth EC, Sclafani F, Cunningham D. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther. 2014; 7: 1001-14. doi: 10.2147/OTT. S44941 PMID: 24959087